Inhalable nanovaccines offer needle-free, mucosal immunity against respiratory diseases like COVID-19, influenza, and TB. Explore delivery mechanisms, key technologies, and future breakthroughs.

Aphios Corporation is pleased to announce that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for its patent application (Application No. 17/699,359), titled ...

The FDA will encourage new clinical trials on the widely used vaccines before approving them for children and healthy adults.

The personalized CRISPR treatment could be the future of gene therapy, but hurdles remain before everyone has access.

ATLANTA and BOSTON, May 28, 2025 (GLOBE NEWSWIRE) -- ABLi Therapeutics ("ABLi”), a biotechnology company developing ...

How CD4+ T cells respond to Chikungunya virus may trigger long-lasting joint pain, mimicking autoimmune disease long after infection clears.

A scientist says he has shown that it’s possible to produce a large amount of virus-like particles using a fully scalable process.

Debiopharm initially received funding from CARB-X in 2017 for pre-clinical development of Debio1453, which inhibits an ...

The World Health Organization (WHO) today posted an outbreak notice about a rise in COVID activity in three of its regions, ...